DNLI Denali Therapeutics
- 24.940
- -0.310-1.23%
Denali Therapeutics News
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SATO VICKI L
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krognes Steve E.
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schuth Alexander O.
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watts Ryan J.
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ho Carole
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-FMR LLC(5.023%),Abigail P. Johnson(5.023%)
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schuth Alexander O.
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ho Carole
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 10-Q: Q2 2024 Earnings Report
Denali Therapeutics | 8-K: Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krognes Steve E.
Analysis
Price Target
No Data
